



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Sandberg et al. Examiner: Borin
Serial No.: 09/580,156 Art Unit: 1631
Filed: May 30, 2000 Docket No.: 25812-5-CIP
Title: ELASTIN PEPTIDE ANALOGS AND USES THEREOF

JUL 12 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

1. This Information Disclosure Statement is filed in accordance with 36 C.F.R. §§ 1.56, 1.97 and 1.98. The items listed on the enclosed Form PTO-1449 may be deemed to be pertinent to the above-identified application and are made of record to assist the Patent and Trademark Office in its examination of this application. The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching.
2. Pursuant to 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.
3. Pursuant to 37 C.F.R. § 1.97(h), the filing of this Information Disclosure Statement shall not be construed as an admission that the information cited in this Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).
4. Pursuant to 37 C.F.R. § 1.97(b), this Information Disclosure Statement is being filed:

() within 3 months of the filing date of a national application; or

() within 3 months of the date of the entry of the national stage as set forth in 37 CFR 1.491 in an international application;

() before the mailing date of a first Office Action on the merits; or

(x) before the mailing of a first Office Action after filing the request for continued examination under 37 C.F.R. 1.114.

It is believed that statements filed within the foregoing periods require neither a fee nor a certification.

The Commissioner is hereby authorized to charge any additional fees required for consideration of this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 02-2051, identifying our Docket No. 25812-5-CIP.

Respectfully Submitted,

Dated: 8/14/03

By: 

W. Scott Harders
Registration No. 42,629

N. Nicole Endejann
Registration No. 50,229

BENESCH, FRIEDLANDER,
COPLAN & ARONOFF, LLP
2300 BP Tower
200 Public Square
Cleveland, Ohio 44114
(216) 363-4453

+

+

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
on a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	09/580,156
Filing Date	05-30-2000
First Named Inventor	Sandberg, et al.
Group Art Unit	1631
Examiner Name	Borin, M
Attorney Docket Number	25812-5-CIP

(use as many sheets as necessary)

Sheet 1 of 4

U.S. PATENT DOCUMENT						
Examiner Initials ¹	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	AA	4,327,078		Charlet et. al.	04/27/1982	
	AB	4,816,513		Bridgham et al.	03/28/1989	
	AC	4,668,476		Bridgham et al.	05/26/1987	
	AD	4,983,382		Wilmott et al.	01/08/1991	
	AE	5,140,043		Darr et al.	08/18/1992	
	AF	5,122,536		Perricone	06/16/1992	
	AG	4,891,227		Thaman et al.	01/02/1990	
	AH	4,891,228		Thaman et al.	01/02/1009	
	AI	4,603,146		Kligman	07/29/1986	
	AJ	4,877,805		Kligman	10/31/1989	
	AK	4,474,763		Lubowe	10/02/1984	
	AL	4,591,501		Cioca	05/27/1986	
	AM	4,659,740		Usher	04/21/1987	
	AN	4,963,656		Mitani	10/16/1990	
	AO	5,017,691		Lee	05/21/1991	
	AP	5,079,003		Scaffidi et al.	01/07/1992	
	AO	5,223,420		Rabaud et al.	06/29/1993	
	AR	5,523,291		Janzen et al.	06/04/1996	
	AS	5,648,209		Avrameas et al.	07/15/1997	
	AT	5,736,537		Gubernick et al.	04/07/1998	

[illegible]

Examiner
Signature

Date Considered

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid OMB control number.

~~Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.~~

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number	09/580,156
Filing Date	05-30-2000
First Named Inventor	Sandberg, et al.
Group Art Unit	1631
Examiner Name	Borin, M
Attorney Docket Number	25812-5-CIP

Sheet 2 of 4

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	BA	6,025,347		Gubernick et al.	02/15/2000	
	BB	5,945,409		Crandall et al.	08/31/1999	
	BC					
	BD					
	BE					
	BF					
	BG					
	BH					
	BI					
	BJ					
	BK					
	BL					
	BM					
	BN					
	BO					
	BP					
	BQ					
	BR					
	BS					

[illegible]

Date	
Considered	

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

Complete if Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

3

of

4

Application Number

09/580,156

Filing Date

05-30-2000

First Named Inventor

Sandberg et al.

Group Art Unit

1631

Examiner Name

Borin, M

Attorney Docket Number

25812-5-CIP

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BA	Heiber, A.D. et al., Detection of Elastin in the Human Fetal Membranes: Proposed Molecular Basis for Elasticity; Placenta; vol. 18; pp. 301-312; 1997.	
	BB	Gibson, M.A. et al., Further Characterization of Proteins Associated with Elastic Fibre Microfibrils Including the Molecular Cloning of MAGP-2 (MP25); The Journal of Biological Chemistry; vol. 271, No. 2 pp. 1096-1103; Jan. 12, 1996.	
	BC	Price, L.S.C. et al., Valyl-Alanyl-Prolyl-Glycine (VAPG) Serves as a Quantitative Marker for Human Elastins; Matrix; vol. 13 pp. 307-311; 1993.	
	BD	Blankenship, J.W. et al., Oxysterol Incorporation Into Rat Aorta Resulting in Elastin Compositional Changes; Lipids; vol. 26, No. 5; pp. 381-384; 1991.	
	BE	Sandberg, L.B. et al., Quantitation of Elastin in Tissues and Culture: Problems Related to the Accurate Measurement of Small Amounts of Elastin With Special Emphasis on the Rat; Connective Tissue Research; vol. 25, pp. 139-148; 1990.	
	BF	Sandberg, L.B. et al., Structural Guidelines for an Acceptable Elastin and Tropoelastin: Application Towards Quantitation of Elastin Accumulation in Tissue Culture; Elastin: Chemical and Biological Aspects (Reprinted); pp. 22-24; 1009.	
	BG	Sandberg, L.B. et al., Quantitation of Elastin Through Measurement of Its Pentapeptide Content; Biochemical and Biophysical Research Communications; vol. 136, No.2 pp. 672-678; Apr. 29, 1986.	
	BH	Database Caplus, AN 108:167920. Bayer et al. Z. Naturforsch., C: Biosci, 42(4), 455-60, Apr. 1987.	
	BI	Hunninghake et al. Science, 212, 925-927, May 1981.	
	BJ	Database Caplus, DN 127:219499. Morrelli et al. J. Pept. Res., 49 (6), 429-499, Jun. 1997.	
	BK	Database Caplus, DN 122:102414. Bisaccia et al. Int. J. Pept. Res, 44, 332-341, Apr. 1994.	

Examiner
Signature

Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

4

of

4

Complete if Known

Application Number	09/580,156
Filing Date	05-30-2000
First Named Inventor	Sandberg, et al.
Group Art Unit	1631
Examiner Name	Borin, M
Attorney Docket Number	25812-5-CIP

JUL 12 2004

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	TECH CENTER 1000/2000
	CA	Database CAPLUS, AN 115:65185, DOI, R. et al., Effects of synthetic human pancreastatin on pancreatic secretion and blood flow in rats and dogs. Peptides. 1991, vol. 12(3), pages 449-502.	
	CB	Database CAPLUS, AN 107:54378, RAJU, K. et al., Primary structure of bovine elastin a, b, and c deduced from the sequences of cDNA clones. J. Biol. Chem., 1987, 262(12), pages 5755-5762.	
	CC	Database CAPULS, AN 107:191131, CHARTEN et al. QSAR for peptide bioactivities. Further studies. Pharmacochem. Libr. 1987, vol. 10, pages 285-290.	
	CD	Database CAPULS, 129:187343, LOGRANO, M. et al., Identification of elastin peptides with vasorelaxant activity on rat thoracic aorta. Int. J. Biochem. Cell Biol., 1998, vol. 30 pages 497-503.	
	CE	FERRANCE, J., Examiner's first report on patent application no. 30854/99 by Connective Tissue Imagineering LLC, 2001.	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.